By Colin Kellaher

Sema4 Holdings Corp. on Monday said it plans to exit the reproductive and women’s health testing business and cut roughly a third of its workforce, as the health-intelligence company shifts its focus to its high-growth, high-margin pediatric and rare-disease business.

As part of the restructuring, Sema4 said it plans to close its laboratory in Stamford, Conn., and eliminate about 500 jobs.

Sema4 said it determined that its reproductive-health business was unsustainable and couldn’t be restructured to allow for profitable growth and cash preservation, adding that efforts to sell the business as a going concern had failed.

The company said it plans to consolidate its remaining testing services at its Gaithersburg, Md., laboratory.

Sema4 said it will stop accepting samples for reproductive and women’s health tests on Dec. 14 and exit the business by the end of the first quarter of 2023.

Write to Colin Kellaher at [email protected]

Go to Source
Date: November 14, 2022, 1:42 pm